AstraZeneca's FluMist gets FDA nod for home use in US

Full story: https://grafa.com/news/united-states-astrazeneca-s-flumist-gets-fda-nod-for-home-use-in-us-277461

AstraZeneca (NASDAQ:AZN) has secured approval from the US Food and Drug Administration (FDA) for the self-administration of FluMist, a needle-free nasal spray influenza vaccine.

The approval by the US Food and Drug Administration (FDA) was based on a comprehensive submission, which included results from a usability study demonstrating that individuals over 18 years of age could self-administer or administer FluMist to eligible individuals 2-49 years of age.

This marks the first influenza vaccine in the US approved for self-administration by adults up to 49 years old and caregiver-administration for individuals aged 2-17 years.

"For the first time, families and caregivers will be able to protect themselves against influenza with a needle-free, self-administered vaccine, from the convenience of their own home," said Dr. Ravi Jhaveri, Division Head of Infectious Diseases at Northwestern University.

This approval is an important step forward in making vaccines more accessible to fight the high annual burden of influenza.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

2

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":351505030406408,"tweetId":"351505030406408","gmtCreate":1726855311241,"gmtModify":1726858540983,"author":{"id":4169784042383112,"idStr":"4169784042383112","authorId":4169784042383112,"authorIdStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","vip":2,"userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":179,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/807ee98baed98a91dc8384d7e12ed3a4"}],"coverImages":[],"title":"AstraZeneca's FluMist gets FDA nod for home use in US","html":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/807ee98baed98a91dc8384d7e12ed3a4\"></p>\n<p>Full story: <a href=\"https://grafa.com/news/united-states-astrazeneca-s-flumist-gets-fda-nod-for-home-use-in-us-277461?utm_source=ttmfinancial&amp;utm_medium=social&amp;utm_campaign=277461&amp;referralcode=A314DFDBE96C354756A893C6E3E02493\">https://grafa.com/news/united-states-astrazeneca-s-flumist-gets-fda-nod-for-home-use-in-us-277461</a></p>\n<p>AstraZeneca <a href=\"https://grafa.com/asset/astrazeneca-plc-adr-11564-azn.nasdaq\">(NASDAQ:AZN)</a> has secured approval from the US Food and Drug Administration (FDA) for the self-administration of FluMist, a needle-free nasal spray influenza vaccine.</p> \n<p><span>The approval by the US Food and Drug Administration (FDA) was based on a comprehensive submission, which included results from a usability study demonstrating that individuals over 18 years of age could self-administer or administer&nbsp;</span><span>FluMist</span><span> to eligible individuals 2-49 years of age.</span></p> \n<p>This marks the first influenza vaccine in the US approved for self-administration by adults up to 49 years old and caregiver-administration for individuals aged 2-17 years.</p> \n<p>\"For the first time, families and caregivers will be able to protect themselves against influenza with a needle-free, self-administered vaccine, from the convenience of their own home,\" said Dr. Ravi Jhaveri, Division Head of Infectious Diseases at Northwestern University.</p> \n<p>This approval is an important step forward in making vaccines more accessible to fight the high annual burden of influenza.</p></body></html>","htmlText":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/807ee98baed98a91dc8384d7e12ed3a4\"></p>\n<p>Full story: <a href=\"https://grafa.com/news/united-states-astrazeneca-s-flumist-gets-fda-nod-for-home-use-in-us-277461?utm_source=ttmfinancial&amp;utm_medium=social&amp;utm_campaign=277461&amp;referralcode=A314DFDBE96C354756A893C6E3E02493\">https://grafa.com/news/united-states-astrazeneca-s-flumist-gets-fda-nod-for-home-use-in-us-277461</a></p>\n<p>AstraZeneca <a href=\"https://grafa.com/asset/astrazeneca-plc-adr-11564-azn.nasdaq\">(NASDAQ:AZN)</a> has secured approval from the US Food and Drug Administration (FDA) for the self-administration of FluMist, a needle-free nasal spray influenza vaccine.</p> \n<p><span>The approval by the US Food and Drug Administration (FDA) was based on a comprehensive submission, which included results from a usability study demonstrating that individuals over 18 years of age could self-administer or administer&nbsp;</span><span>FluMist</span><span> to eligible individuals 2-49 years of age.</span></p> \n<p>This marks the first influenza vaccine in the US approved for self-administration by adults up to 49 years old and caregiver-administration for individuals aged 2-17 years.</p> \n<p>\"For the first time, families and caregivers will be able to protect themselves against influenza with a needle-free, self-administered vaccine, from the convenience of their own home,\" said Dr. Ravi Jhaveri, Division Head of Infectious Diseases at Northwestern University.</p> \n<p>This approval is an important step forward in making vaccines more accessible to fight the high annual burden of influenza.</p></body></html>","text":"Full story: https://grafa.com/news/united-states-astrazeneca-s-flumist-gets-fda-nod-for-home-use-in-us-277461 AstraZeneca (NASDAQ:AZN) has secured approval from the US Food and Drug Administration (FDA) for the self-administration of FluMist, a needle-free nasal spray influenza vaccine. The approval by the US Food and Drug Administration (FDA) was based on a comprehensive submission, which included results from a usability study demonstrating that individuals over 18 years of age could self-administer or administer FluMist to eligible individuals 2-49 years of age. This marks the first influenza vaccine in the US approved for self-administration by adults up to 49 years old and caregiver-administration for individuals aged 2-17 years. \"For the first time, families and caregivers will be able to protect themselves against influenza with a needle-free, self-administered vaccine, from the convenience of their own home,\" said Dr. Ravi Jhaveri, Division Head of Infectious Diseases at Northwestern University. This approval is an important step forward in making vaccines more accessible to fight the high annual burden of influenza.","highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/351505030406408","repostId":0,"isVote":1,"tweetType":1,"viewCount":171,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["AZN","CFA.SI"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":988,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/351505030406408"}